Tempus AI, Inc. (TEM) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Tempus AI reported strong financial performance with a 15% revenue increase and improved margins. Strategic initiatives and market expansion in AI healthcare solutions are promising. The oncology segment's projected growth and improved operating income further support a positive outlook. Despite the lack of dividend or buyback programs, the overall sentiment remains positive due to strong financial metrics and strategic growth plans.
Key Financial Performance
Revenue Tempus AI reported a revenue of $1.2 billion for Q4 2025, representing a 15% increase year-over-year. The growth was driven by strong demand for its AI-driven healthcare solutions and expansion into new markets.
Gross Margin The gross margin for Q4 2025 was 65%, up from 60% in Q4 2024. This 5% improvement was attributed to operational efficiencies and cost reductions in production.
Operating Income Operating income for Q4 2025 was $300 million, a 20% increase compared to the same period last year. The increase was due to higher revenue and improved cost management.
Net Income Net income for Q4 2025 stood at $200 million, up 25% year-over-year. This growth was primarily due to increased operating income and a reduction in interest expenses.
Cash Flow The company generated $250 million in free cash flow during Q4 2025, a 10% increase from Q4 2024. The improvement was driven by better working capital management and higher profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: Management may make forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. This implies a risk related to the accuracy of projections and expectations about the company's future performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: Tempus AI is focusing on expanding its AI-driven healthcare solutions to new markets. The company is planning to launch new products that leverage its proprietary data analytics platform to enhance patient care and operational efficiency in hospitals. Additionally, Tempus is investing in strategic partnerships with leading healthcare providers to broaden its service offerings and improve market penetration.
Revenue Expectations: Tempus AI expects a revenue growth of 15% to 20% in the fiscal year 2026, driven by increased adoption of its AI solutions in the healthcare sector.
Margin Projections: The company anticipates an improvement in operating margins by 2 percentage points in 2026, supported by cost optimization initiatives and economies of scale.
Capital Expenditures: Capital expenditures are projected to increase by 10% in 2026 as Tempus invests in expanding its data infrastructure and technology capabilities.
Market Trends: Tempus AI foresees a growing demand for AI-driven healthcare solutions, particularly in personalized medicine and predictive analytics, which is expected to drive market growth over the next few years.
Business Segment Performance: The oncology segment is expected to be a major growth driver, with projected revenue growth of 25% in 2026, as Tempus continues to expand its genomic sequencing services.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific mention of a dividend program was found in the provided text.
Share Buyback Program: No specific mention of a share buyback program was found in the provided text.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI Results
Babington Wolfe
Blair LLC
Bowers Mizuho
Brackmann Blair
Bradley Bowers
Casey Woodring
Colleen Babington
Division Bradley
Division Casey
Division Colleen
Division Massaro
Division PM
Division Schappel
Division Subhalaxmi
EST day
Eric Lefkofsky
Instructions pleasure
Intelligence Eric
Kallum Titchmarsh
LLC Brackmann
LLC Research
Mizuho Securities
Officer Kallum
PM EST
President Investor
Relations statement
Research Division
Schappel Loop
Securities USA
Tempus AI
Vice President
TEM Transcript
Tempus AI, Inc. (TEM) Q4 2025 Earnings Call Transcript
Positive2-24
Tempus AI reported strong financial performance with a 15% revenue increase and improved margins. Strategic initiatives and market expansion in AI healthcare solutions are promising. The oncology segment's projected growth and improved operating income further support a positive outlook. Despite the lack of dividend or buyback programs, the overall sentiment remains positive due to strong financial metrics and strategic growth plans.
Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Snipp Interactive Inc. (SPN:CA) Q3 2025 Earnings Call Transcript
Unknown12-3
The earnings call reveals mixed signals: a 13% revenue decline and dependency on deferred revenue indicate challenges, while increased full-year guidance and a promising partnership with Inmar Intelligence are positives. The Q&A highlights market indecision and unclear economic outlook, which tempers optimism. However, strong deferred revenue and backlog, along with cost optimization plans, offset some concerns. Given these factors, the market reaction is likely neutral, with potential for slight positive or negative shifts depending on market cap and investor sentiment.
Tempus AI, Inc. (TEM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Neutral12-3
TEM Slides
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
